AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39022889 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 32
Study 39023055 — intervention group
Group type: EXPERIMENTAL
Intervention: PRADO-IC program
Number of subjects: 404
Study 39023055 — intervention group
Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 404
Study 39023063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 1059
Study 39023063 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 1059
Study 39023063 — intervention group
Group type: COMPARATOR
Intervention: No oral anticoagulants (OAC)
Number of subjects: 1059
Study 39023092 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlifidase
Number of subjects: 30
Study 39023092 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis (PLEX)
Number of subjects: 30
Study 39023141 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter ablation within 4 weeks after randomization
Number of subjects: 1548
Study 39023141 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1548
Study 39023141 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 1548
Study 39023142 — intervention group
Group type: EXPERIMENTAL
Intervention: CaRi-Heart Risk
Number of subjects: 2300000
Study 39023142 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not explicitly defined)
Number of subjects: 2300000
Study 39023253 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy for 2 years, followed by endocrine therapy for a total of at least 5 years.
Number of subjects: 0
Study 39023253 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy only for at least 5 years.
Number of subjects: 0
Study 39023253 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy
Number of subjects: 0
Study 39023253 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy only
Number of subjects: 0
Study 39023287 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Oleclumab
Number of subjects: 999
Study 39023287 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Monalizumab
Number of subjects: 999
Study 39023287 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab + Placebo
Number of subjects: 999
Study 39023393 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 119
Study 39023393 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 119
Study 39023418 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed monitoring and management practices
Number of subjects: 435971
Study 39023418 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins
Number of subjects: 435971
Study 39023418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitors
Number of subjects: 435971
Study 39023418 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements
Number of subjects: 435971
Study 39023418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall standard of care
Number of subjects: 435971
Study 39023538 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 247
Study 39023538 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation (HA)
Number of subjects: 247
Study 39023538 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (NA)
Number of subjects: 247
Study 39023538 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA
Number of subjects: 247
Study 39023538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyser surface area
Number of subjects: 247
Study 39023538 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal jugular vein vascular access site
Number of subjects: 247
Study 39023547 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Management and Survivorship Handbook (SMSH)
Number of subjects: 462
Study 39023547 — intervention group
Group type: COMPARATOR
Intervention: Symptom Management and Survivorship Handbook (SMSH) + Telephone Interpersonal Counseling (TIPC)
Number of subjects: 462
Study 39023547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity SMSH
Number of subjects: 462
Study 39023568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 0
Study 39023568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39023880 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg orally once daily for up to 52 weeks
Number of subjects: 74
Study 39023880 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once daily for up to 52 weeks
Number of subjects: 74
Study 39023880 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 74
Study 39023880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 39023893 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Personalized Feedback (EPF) only
Number of subjects: 2079
Study 39023893 — intervention group
Group type: EXPERIMENTAL
Intervention: Silvercloud only (CBT-based)
Number of subjects: 2079
Study 39023893 — intervention group
Group type: EXPERIMENTAL
Intervention: Silvercloud plus EPF
Number of subjects: 2079
Study 39023893 — intervention group
Group type: EXPERIMENTAL
Intervention: Headspace only (mindfulness-based)
Number of subjects: 2079
Study 39023893 — intervention group
Group type: EXPERIMENTAL
Intervention: Headspace plus EPF
Number of subjects: 2079
Study 39023900 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 minutes per week of exercise therapy
Number of subjects: 53
Study 39023900 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 minutes per week of exercise therapy
Number of subjects: 53
Study 39023900 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 minutes per week of exercise therapy
Number of subjects: 53
Study 39023900 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 minutes per week of exercise therapy
Number of subjects: 53
Study 39023900 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 minutes per week of exercise therapy
Number of subjects: 53
Study 39023900 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 minutes per week of exercise therapy
Number of subjects: 53
Study 39023984 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive bias modification for interpretation (CBM-I)
Number of subjects: 1234
Study 39023984 — intervention group
Group type: COMPARATOR
Intervention: Active psychoeducation
Number of subjects: 1234
Study 39023984 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I with low-intensity telecoaching
Number of subjects: 1234
Study 39023984 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I without coaching
Number of subjects: 1234
Study 39024000 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame-RFA plus standard care
Number of subjects: 96
Study 39024000 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 96
Study 39024005 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Incident Report System for Students
Number of subjects: 223
Study 39024037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks)
Number of subjects: 130
Study 39024237 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Health Program (OHP)
Number of subjects: 30
Study 39024364 — intervention group
Group type: EXPERIMENTAL
Intervention: Early norepinephrine (NE) administration
Number of subjects: 100
Study 39024364 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 39024366 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and Well-Being Committees (HaWCs) intervention
Number of subjects: 1200
Study 39024366 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no intervention)
Number of subjects: 1200
Study 39024543 — intervention group
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec (6 × 10^13 vg/kg infusion)
Number of subjects: 134
Study 39024542 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly carfilzomib (56 mg/m2) plus lenalidomide and dexamethasone (KRd56)
Number of subjects: 454
Study 39024542 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27)
Number of subjects: 454
Study 39024777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib-based regimen
Number of subjects: 137
Study 39024777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib-based regimen as second-line therapy
Number of subjects: 137
Study 39024777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib-based regimen as third-or-post-line therapy
Number of subjects: 137
Study 39024777 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain radiotherapy (BRT)
Number of subjects: 137
Study 39024777 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (adverse events)
Number of subjects: 137
Study 39024845 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PSI-rTMS (10 Hz, 80% resting motor threshold, 5 daily sessions for 1 week, followed by weekly maintenance for 7 weeks)
Number of subjects: 25
Study 39024845 — intervention group
Group type: COMPARATOR
Intervention: Sham PSI-rTMS
Number of subjects: 25
Study 39024845 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PSI-rTMS
Number of subjects: 25
Study 39024964 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 0
Study 39024964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39025065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 77
Study 39025066 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO1020 (15 μg per dose, 2 doses, administered 28 days apart)
Number of subjects: 14138
Study 39025066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14138
Study 39025066 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO1020 (1 or 2 doses)
Number of subjects: 14138
Study 39025066 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO1020
Number of subjects: 14138
Study 39025092 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial oral antibiotics (coformulated amoxicillin 100 mg/kg per day and clavulanic acid 12.5 mg/kg per day for patients younger than 5 years; dicloxacillin 200 mg/kg per day for patients aged 5 years or older)
Number of subjects: 248
Study 39025092 — intervention group
Group type: COMPARATOR
Intervention: Initial intravenous antibiotics (ceftriaxone 100 mg/kg per day in one dose)
Number of subjects: 248
Study 39025100 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended mesenteric resection
Number of subjects: 139
Study 39025100 — intervention group
Group type: COMPARATOR
Intervention: Mesenteric sparing resection
Number of subjects: 139
Study 39025255 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study 39025255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39025264 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-CBD cream
Number of subjects: 19
Study 39025264 — intervention group
Group type: COMPARATOR
Intervention: vehicle cream
Number of subjects: 19
Study 39025698 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX-24 2.2 mcg dose
Number of subjects: 200
Study 39025698 — intervention group
Group type: COMPARATOR
Intervention: Prevnar 20® (PCV20)
Number of subjects: 200
Study 39025785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 50
Study 39025785 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 90 mg
Number of subjects: 50
Study 39025812 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention including a patient information leaflet and key questions diagram, and an option grid.
Number of subjects: 8
Study 39025812 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based recommendations for treatment following ACL rupture.
Number of subjects: 8
Study 39025948 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG + NIVO
Number of subjects: 0
Study 39025948 — intervention group
Group type: COMPARATOR
Intervention: NIVO
Number of subjects: 0
Study 39025971 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (200 mg; twice daily for 5 days) with aspirin (325 mg for 5 days)
Number of subjects: 113
Study 39025971 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (200 mg; twice daily for 5 days) with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Number of subjects: 113
Study 39025971 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (200 mg; twice daily for 5 days) without aspirin or clopidogrel
Number of subjects: 113
Study 39025971 — intervention group
Group type: COMPARATOR
Intervention: Placebo with aspirin (325 mg for 5 days)
Number of subjects: 113
Study 39025971 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Number of subjects: 113
Study 39025971 — intervention group
Group type: COMPARATOR
Intervention: Placebo without aspirin or clopidogrel
Number of subjects: 113
Study 39026124 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIKES protocol (nurses trained for 1 hour)
Number of subjects: 136
Study 39026124 — intervention group
Group type: COMPARATOR
Intervention: Routine care (standard of care)
Number of subjects: 136
Study 39026124 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIKES protocol
Number of subjects: 136
Study 39026124 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 136
Study 39026154 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT + CAVI (n=8)
Number of subjects: 18
Study 39026154 — intervention group
Group type: COMPARATOR
Intervention: OMT (n=10)
Number of subjects: 18
Study 39026165 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron transdermal delivery system (GTDS) combined with Dexamethasone
Number of subjects: 54
Study 39026172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuin-A assessment in MASLD patients
Number of subjects: 100
Study 39026197 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (33.5 ± 0.5 C) for 72 hours
Number of subjects: 426
Study 39026197 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37.0 ± 0.5 C) for 72 hours
Number of subjects: 426
Study 39026236 — intervention group
Group type: EXPERIMENTAL
Intervention: ATSB deployment (intervention)
Number of subjects: 20
Study 39026236 — intervention group
Group type: COMPARATOR
Intervention: Control (no ATSB deployment)
Number of subjects: 20
Study 39026266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (40 min daily over three consecutive days)
Number of subjects: 33
Study 39026266 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active placebo, 40 min daily over three consecutive days)
Number of subjects: 33
Study 39026289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI before SRS and follow-up MRIs every 3 months for 24 months
Number of subjects: 0
Study 39026289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI protocol including T2-weighted, contrast-enhanced T1-weighted imaging, diffusion-weighted imaging, and dynamic susceptibility contrast imaging
Number of subjects: 0
Study 39026289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards analysis
Number of subjects: 0
Study 39026289 — intervention group
Group type: EXPERIMENTAL
Intervention: DICE similarity coefficients calculation
Number of subjects: 0
Study 39026306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole oral solution (1 mg/mL, range: 2-20 mg, starting dose of 2 mg)
Number of subjects: 121
Study 39026306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 39026547 — intervention group
Group type: EXPERIMENTAL
Intervention: ReFerm enema
Number of subjects: 30
Study 39026552 — intervention group
Group type: EXPERIMENTAL
Intervention: New clinically implemented diagnostic imaging modalities
Number of subjects: 0
Study 39026552 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging stratification
Number of subjects: 0
Study 39026552 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment requirements in GCA patients
Number of subjects: 0
Study 39026552 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment needs in PMR patients
Number of subjects: 0
Study 39026552 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic role of imaging
Number of subjects: 0
Study 39026620 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) as a biological therapy for preventing postoperative AF
Number of subjects: 0
Study 39026620 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study 39026628 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6796
Study 39026628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6796
Study 39027143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg intravenously every three weeks for four doses, then 1000 mg every six weeks)
Number of subjects: 209
Study 39027228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic Foot Care Group (DFCG) via Facebook
Number of subjects: 32
Study 39027228 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 39027228 — intervention group
Group type: EXPERIMENTAL
Intervention: DFCG
Number of subjects: 32
Study 39027419 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereopure antisense oligonucleotides for allele-selective lowering of mutant huntingtin
Number of subjects: 0
Study 39027419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39027664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (0.3 g inorganic nitrate twice/day)
Number of subjects: 11
Study 39027664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted juice)
Number of subjects: 11
Study 39028043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation with ankle movement treatment 3 times per week for 4 weeks
Number of subjects: 64
Study 39028043 — intervention group
Group type: COMPARATOR
Intervention: Regular physiotherapy sessions
Number of subjects: 64
Study 39028057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic mobilisation with conventional physical therapy
Number of subjects: 44
Study 39028057 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 44
Study 39028323 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1364
Study 39028323 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive three-layer decision tree model
Number of subjects: 1364
Study 39028352 — intervention group
Group type: EXPERIMENTAL
Intervention: oPEP device with Sniff breathing (Sniff-PEP) for 1 month, 10-15 min 3-4 times a day
Number of subjects: 15
Study 39028360 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 18
Study 39028360 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (sensor-augmented pump) insulin therapy
Number of subjects: 18
Study 39028385 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP implementation strategies including adherence supporters, community workshops, and check-in calls.
Number of subjects: 20
Study 39028385 — intervention group
Group type: COMPARATOR
Intervention: Comparison fisherfolk community with better healthcare access (control group).
Number of subjects: 20
Study 39028412 — intervention group
Group type: EXPERIMENTAL
Intervention: SFX-01 300 mg BD for 28 days
Number of subjects: 105
Study 39028412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 39028573 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39028616 — intervention group
Group type: EXPERIMENTAL
Intervention: FcE-aCTLA-4, anti-PD-1, doxorubicin with LIPU/MB
Number of subjects: 4
Study 39028616 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, anti-PD-1 with LIPU/MB
Number of subjects: 4
Study 39028616 — intervention group
Group type: EXPERIMENTAL
Intervention: FcE-aCTLA-4
Number of subjects: 4
Study 39028663 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal Control (EtC)
Number of subjects: 210
Study 39028663 — intervention group
Group type: COMPARATOR
Intervention: Manual Control (MC)
Number of subjects: 210
Study 39028670 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted diagnosis
Number of subjects: 628
Study 39028670 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnosis
Number of subjects: 628
Study 39028670 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint-AI model
Number of subjects: 628
Study 39028763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous dexamethasone
Number of subjects: 120
Study 39028763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 39028879 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 1234
Study 39028879 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1234
Study 39028879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 1234
Study 39028879 — intervention group
Group type: COMPARATOR
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 1234
Study 39028879 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT
Number of subjects: 1234
Study 39028902 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB-185 3840 units/kg
Number of subjects: 647
Study 39028902 — intervention group
Group type: COMPARATOR
Intervention: casirivimab/imdevimab 1200 mg
Number of subjects: 647
Study 39028916 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-Vaxx plus chemotherapy
Number of subjects: 36
Study 39028916 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy
Number of subjects: 36
Study 39028916 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-Vaxx
Number of subjects: 36